2 results
Approved WMORecruiting
The aim of this study is to evaluate the difference in the fraction of patients that have disease progression within 6 months after applying 177Lu-PSMA RLT in patients with low volume, hormone sensitive metastatic prostate cancer. Ultimately, the…
Approved WMOCompleted
The aim of this study is to evaluate the dosimetry and toxicity of Lutetium-177-PSMA-617, in patients with low volume, hormone sensitive metastatic prostate cancer.